From malignant hypertension to hypertension-MOD: A modern definition for an old but still dangerous emergency

Journal of Human Hypertension

Volumn 30, Issue 8, 2016, Pages 463-466

  Cremer, A ^a   Amraoui, F ^b   Lip, G Y H ^c   Morales, E ^d   Rubin, S ^a   Segura, J ^d   Van Den Born, B J ^b   Gosse, P ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRAIN; DIAGNOSTIC TEST; DISEASE SEVERITY; EMERGENCY CARE; HEART; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTENSION RETINOPATHY; HYPERTENSION WITH MULTIORGAN DAMAGE; INCIDENCE; KIDNEY; MALIGNANT HYPERTENSION; MULTIPLE ORGAN FAILURE; PAPILLEDEMA; PREVALENCE; PROGNOSIS; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SCLERODERMA; TARGET ORGAN; THROMBOTIC THROMBOCYTOPENIC PURPURA; WHITE MATTER LESION; BLOOD PRESSURE; DRUG EFFECTS; EARLY DIAGNOSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RISK FACTOR; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EARLY DIAGNOSIS; HUMANS; HYPERTENSION, MALIGNANT; MULTIPLE ORGAN FAILURE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84947604134     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2015.112     Document Type: Review

References (23)

1. Lip GY, Beevers M, Beevers DG. Do patients with de novo hypertension differ from patients with previously known hypertension when malignant phase hypertension occurs? Am J Hypertens 2000; 13: 934-939.
2. Ahmed ME, Walker JM, Beevers DG, Beevers M. Lack of difference between malignant and accelerated hypertension. Br Med J (Clin Res Ed) 1986; 292: 235-237.
3. Gonzalez R, Morales E, Segura J, Ruilope LM, Praga M. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant 2010; 25: 3266-3272.
4. Lip GY, Beevers M, Beevers DG. Does renal function improve after diagnosis of malignant phase hypertension? J Hypertens 1997; 15: 1309-1315.
5. Amraoui F, Van Der Hoeven NV, Van Valkengoed IG, Vogt L, Van Den Born BJ. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich) 2014; 16: 122-126.
6. Pak KJ, Hu T, Fee C, Wang R, Smith M, Bazzano LA. Acute hypertension: a systematic review and appraisal of guidelines. Ochsner J 2014; 14: 655-663.
7. Shantsila A, Shantsila E, Lip GY. Malignant hypertension: a rare problem or is it underdiagnosed? Curr Vasc Pharmacol 2010; 8: 775-779.
8. van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans GA. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens 2006; 24: 2299-2304.
9. Lip GY, Beevers M, Beevers G. The failure of malignant hypertension to decline: a survey of 24 years' experience in a multiracial population in England. J Hypertens 1994; 12: 1297-1305.
10. Lane DA, Lip GY, Beevers DG. Improving survival of malignant hypertension patients over 40 years. Am J Hypertens 2009; 22: 1199-1204.
11. Leishman AW. Hypertension: treated and untreated; a study of 400 cases. Br Med J 1959; 1: 1361-1368.
12. Lip GY, Beevers M, Beevers DG. Complications and survival of 315 patients with malignant-phase hypertension. J Hypertens 1995; 13: 915-924.
13. Shantsila A, Lane DA, Beevers DG, Lip GY. Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension: the West Birmingham Malignant Hypertension study. J Hypertens 2012; 30: 974-979.
14. Pimenta E, Calhoun DA. Hypertensive crisis: forget the numbers. J Hypertens 2012; 30: 882-883.
15. Gosse P, Coulon P, Papaioannou G, Litalien J, Lemetayer P. Impact of malignant arterial hypertension on the heart. J Hypertens 2011; 29: 798-802.
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357.
17. Lip GY, Beevers M, Dodson PM, Beevers DG. Severe hypertension with lone bilateral papilloedema: a variant of malignant hypertension. Blood Press 1995; 4: 339-342.
18. Amraoui F, van Montfrans GA, van den Born BJ. Value of retinal examination in hypertensive encephalopathy. J Hum Hypertens 2009; 4: 274-279.
19. Akoudad S, Portegies ML, Koudstaal PJ, Hofman A, van der Lugt A, Ikram MA et al. Cerebral microbleeds are associated with an increased risk of stroke: The Rotterdam Study. Circulation 2015; 132: 509-516.
20. Griffin KA, Polichnowski A, Litbarg N, Picken MA, Venkatachalam M, Bidani AK. Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant Nephrosclerosis Model. Hypertension 2014; 64: 801-807.
21. van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005; 45: 246-251.
22. Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GY. A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: the West Birmingham Malignant Hypertension project. Int J Cardiol 2013; 167: 67-72.
23. van den Born BJ, Beutler JJ, Gaillard CA, de Gooijer A, van den Meiracker AH, Kroon AA. Dutch guideline for the management of hypertensive crisis-2010 revision. Neth J Med 2011; 69: 248-255.